153 completed, 54 terminated, 52 unknown, 41 recruiting. 198 Phase 2, 99 Phase 1, 66 Phase 3, 9 Phase 4, 8 Not applicable.
Follow liposomal doxorubicin: new trials by email Literature Review of liposomal doxorubicin trials Research Report on liposomal doxorubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma Doxorubicin - Sarcoma | Phase 2 | Recruiting | University of Colorado, Denver | 20 | 2026-12-01 | 2026-02-05 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-16 |
| Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Carboplatin, Bevacizumab - Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 176 | 2026-09-30 | 2026-08-20 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-20 |
| A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) Mocertatug rezetecan (Mo-Rez), Carboplatin, Paclitaxel - Ovarian Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 690 | 2026-09-08 | 2026-10-01 |
| SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma Toripalimab, Liposomal doxorubicin, Stereotactic body radiotherapy (SBRT) - Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 39 | 2026-09-01 | 2026-09-14 |
| Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Pegylated liposomal doxorubicin, Paclitaxel - Kaposi Sarcoma, HIV-1-infection | Phase 3 | Not yet recruiting | AIDS Malignancy Consortium | 130 | 2026-09-01 | 2026-01-23 |
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-08-31 | 2026-07-27 |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan - Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer | Phase 3 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 460 | 2026-07-15 | 2026-09-23 |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-07-01 | 2026-06-29 |
| An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Recruiting | Genmab | 82 | 2026-06-26 | 2026-10-06 |
| A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) - Ovarian Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 450 | 2026-06-18 | 2026-10-15 |
| Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 30 | 2026-03-03 | 2026-04-24 |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes Vincristine, Doxorubicin, Cyclophosphamide - Metastatic Ewing Sarcoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 15 | 2026-02-05 | 2026-09-25 |
| Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY) Pegylated liposomal doxorubicin - Advanced Soft Tissue Sarcoma | Phase 2 | Recruiting | National Health Research Institutes, Taiwan | 81 | 2025-12-31 | 2026-07-02 |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-29 | 2026-07-21 |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression INCB123667, Investigator's choice of chemotherapy - Ovarian Cancer | Phase 3 | Recruiting | Incyte Corporation | 466 | 2025-12-09 | 2026-10-15 |
| A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Sofetabart Mipitecan, Paclitaxel, Topotecan - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 3 | Recruiting | Eli Lilly and Company | 1630 | 2025-10-22 | 2026-10-08 |
| A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 450 | 2025-08-04 | 2026-07-07 |
Showing 20 of 346. Sign in to see all of them.
Ovarian Neoplasms (107) · Breast Neoplasms (76) · Fallopian Tube Neoplasms (48) · Multiple Myeloma (32) · Carcinoma, Ovarian Epithelial (28) · Neoplasms (23) · Lymphoma (17) · Sarcoma (13) · Neoplasm Metastasis (12) · Recurrence (12) · Triple Negative Breast Neoplasms (12) · Lymphoma, Large B-Cell, Diffuse (11) · Hodgkin Disease (8) · Lymphoma, Non-Hodgkin (8) · Neoplasms, Plasma Cell (6)
National Cancer Institute (NCI) (28) · Merck Sharp & Dohme LLC (15) · M.D. Anderson Cancer Center (8) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (7) · Fudan University (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · AstraZeneca (4) · Eli Lilly and Company (4) · Janssen Research & Development, LLC (4) · National Cancer Institute, Naples (4) · Spanish Breast Cancer Research Group (4) · Sun Yat-sen University (4) · University of Nebraska (4) · Washington University School of Medicine (4) · ARCAGY/ GINECO GROUP (3)
United States (201) · China (55) · Spain (42) · Italy (40) · Canada (34) · United Kingdom (33) · Australia (32) · Belgium (31) · France (30) · South Korea (29) · Germany (28) · Poland (19) · Netherlands (17) · Switzerland (17) · Taiwan (17)
Robert Yarchoan, M.D. (3) · Andrzej J Jakubowiak, MD, PhD (2) · Antonio Lambiase, MD (2) · Breelyn Wilky, MD (2) · Domenica Lorusso, MD (2) · Francesco Perrone, M.D., Ph.D (2) · Francesco Perrone, M.D., Ph.D. (2) · Franco Muggia, MD (2) · James R Berenson, MD (2) · Jane Robertson, BSc, MBCHB, MD (2)
PMID 37407274, PMID 37185961, PMID 35170751, PMID 10655437, PMID 31401903, PMID 33960681, PMID 34037241, PMID 38941593, PMID 41698326, PMID 10694544, PMID 10830142, PMID 11085525, PMID 11165136, PMID 11304695, PMID 11479630, PMID 11807147, PMID 12393992, PMID 12419745, PMID 14998846, PMID 15273730, PMID 15374957, PMID 15542813, PMID 15547525, PMID 15621843, PMID 15641020, PMID 15867204, PMID 16404741, PMID 16754935, PMID 16879771, PMID 16912194, PMID 1695122, PMID 17071492, PMID 17320506, PMID 17336087, PMID 17486128, PMID 17512352, PMID 17654614, PMID 17679727, PMID 17679729, PMID 17925555, PMID 18082257, PMID 18213528, PMID 18234305, PMID 18300257, PMID 18327587, PMID 18572266, PMID 18824292, PMID 18826610, PMID 19110234, PMID 19238149
U10CA180868 (9), 2025 (6), 2009 (5), P30CA036727 (4), 2005 (3), 2018 (3), U10CA021115 (3), 2004 (2), 2019 (2), 2023 (2), N01CM62204 (2), P30CA013330 (2), P30CA060553 (2), P30CA072720 (2), U10CA027469 (2)